Nothing Special   »   [go: up one dir, main page]

EP1947178A4 - Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof - Google Patents

Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof

Info

Publication number
EP1947178A4
EP1947178A4 EP06811775A EP06811775A EP1947178A4 EP 1947178 A4 EP1947178 A4 EP 1947178A4 EP 06811775 A EP06811775 A EP 06811775A EP 06811775 A EP06811775 A EP 06811775A EP 1947178 A4 EP1947178 A4 EP 1947178A4
Authority
EP
European Patent Office
Prior art keywords
human
csf
antigen
monoclonal antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06811775A
Other languages
German (de)
French (fr)
Other versions
EP1947178A1 (en
Inventor
Kantou Nakajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evec Inc
Original Assignee
Evec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc filed Critical Evec Inc
Publication of EP1947178A1 publication Critical patent/EP1947178A1/en
Publication of EP1947178A4 publication Critical patent/EP1947178A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP06811775A 2005-10-26 2006-10-13 Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof Ceased EP1947178A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005311776A JP4736037B2 (en) 2005-10-26 2005-10-26 Human monoclonal antibody binding to human GM-CSF and antigen-binding portion thereof
PCT/JP2006/320502 WO2007049472A1 (en) 2005-10-26 2006-10-13 Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof

Publications (2)

Publication Number Publication Date
EP1947178A1 EP1947178A1 (en) 2008-07-23
EP1947178A4 true EP1947178A4 (en) 2009-03-11

Family

ID=37967585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06811775A Ceased EP1947178A4 (en) 2005-10-26 2006-10-13 Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof

Country Status (4)

Country Link
US (1) US7935795B2 (en)
EP (1) EP1947178A4 (en)
JP (1) JP4736037B2 (en)
WO (1) WO2007049472A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4736037B2 (en) 2005-10-26 2011-07-27 株式会社イーベック Human monoclonal antibody binding to human GM-CSF and antigen-binding portion thereof
CA2641169C (en) * 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
CA2687791A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
RU2526517C2 (en) * 2007-10-25 2014-08-20 Треллис Байосайенс,Инк. Respiratory syncytial virus (rsv) anti-g protein antibodies
MX2010005291A (en) 2007-11-13 2010-11-12 Evec Inc Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same.
JP5476310B2 (en) * 2008-02-14 2014-04-23 株式会社イーベック Monoclonal antibody binding to hGM-CSF and pharmaceutical composition comprising said antibody
JP6014706B2 (en) * 2008-02-14 2016-10-25 株式会社イーベック Monoclonal antibody binding to hGM-CSF and pharmaceutical composition comprising said antibody
JP2012105657A (en) * 2008-02-14 2012-06-07 Evec Inc MONOCLONAL ANTIBODY BINDING TO hGM-CSF AND MEDICAL COMPOSITION CONTAINING THE SAME
KR101761324B1 (en) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 Pain treatment
CA2746827C (en) 2008-12-22 2018-01-23 The University Of Melbourne Osteoarthritis treatment
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
RU2013156435A (en) 2011-07-06 2015-08-20 МорфоСис АГ THERAPEUTIC COMBINATIONS ANTI-CD20 AND ANTI-GM-CSF ANTIBODIES AND THEIR APPLICATIONS
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (en) 2013-02-28 2019-07-01 Biocare Medical Llc Systems and Methods with Anti-p40 Antibodies
MX2016002177A (en) 2013-08-30 2016-06-28 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics.
JP6506267B2 (en) 2013-10-03 2019-04-24 バイオケア メディカル， エルエルシー Anti-SOX 10 Antibody Systems and Methods
MX2016014411A (en) * 2014-05-07 2017-04-06 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound.
JP6490419B2 (en) * 2014-12-24 2019-03-27 学校法人関西医科大学 Regulatory T cell differentiation inducer
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105844A2 (en) * 2004-05-05 2005-11-10 Micromet Ag Preparation of scfv antibody fragments
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5662138A (en) * 1996-06-12 1997-09-02 Wang; Wen-Hsing Drop head structure
DK1294769T3 (en) * 2000-06-16 2011-04-26 Human Genome Sciences Inc Antibodies that immunospecifically bind to BLyS
US7229784B2 (en) * 2000-09-19 2007-06-12 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
PE20021080A1 (en) 2001-04-12 2003-02-12 Boehringer Ingelheim Int A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003040341A2 (en) * 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
WO2003068920A2 (en) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (en) * 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
SI1888643T1 (en) 2005-05-18 2015-03-31 Morphosys Ag Anti-gm-csf antibodies and uses therefor
JP4736037B2 (en) 2005-10-26 2011-07-27 株式会社イーベック Human monoclonal antibody binding to human GM-CSF and antigen-binding portion thereof
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105844A2 (en) * 2004-05-05 2005-11-10 Micromet Ag Preparation of scfv antibody fragments
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BOZINOVSKI STEVEN ET AL: "Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4.", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY APR 2004, vol. 286, no. 4, April 2004 (2004-04-01), pages L877 - L885, XP002505899, ISSN: 1040-0605 *
COOK ANDREW D ET AL: "Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 3, no. 5, 11 June 2001 (2001-06-11), pages 293 - 298, XP021020639, ISSN: 1465-9905 *
FLEETWOOD ANDREW J ET AL: "Functions of granulocyte-macrophage colony-stimulating factor", CRITICAL REVIEWS IN IMMUNOLOGY, CRC PRESS, INC, XX, vol. 25, no. 5, 1 January 2005 (2005-01-01), pages 405 - 428, XP009090869, ISSN: 1040-8401 *
GREEN L L: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004187631, ISSN: 0022-1759 *
GRIFFITHS A D ET AL: "Strategies for selection of antibodies by phage display.", CURRENT OPINION IN BIOTECHNOLOGY FEB 1998, vol. 9, no. 1, February 1998 (1998-02-01), pages 102 - 108, XP002505900, ISSN: 0958-1669 *
HAMILTON J A: "GM-CSF in inflammation and autoimmunity", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 403 - 408, XP004371500, ISSN: 1471-4906 *
HOOGENBOOM H R: "Designing and optimizing library selection strategies for generating high-affinity antibodies", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 62 - 70, XP004034115, ISSN: 0167-7799 *
RATHANASWAMI ET AL: "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 334, no. 4, 9 September 2005 (2005-09-09), pages 1004 - 1013, XP005001490, ISSN: 0006-291X *
SCHÖN M ET AL: "Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY MAY 2000, vol. 114, no. 5, May 2000 (2000-05-01), pages 976 - 983, XP002505897, ISSN: 0022-202X *
See also references of WO2007049472A1 *
SONG-XY ET AL.: "Coming of age: anti-cytokine therapies", MOL INTERV., vol. 2, no. 1, February 2002 (2002-02-01), pages 36-46 *
WEINER LM: "Fully human therapeutic monoclonal antibodies", J IMMUNOTHER, vol. 29, no. 1, - February 2006 (2006-02-01), pages 1-9, XP009118693 *
YAMASHITA NAOMI ET AL: "Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF).", CELLULAR IMMUNOLOGY OCT 2002, vol. 219, no. 2, October 2002 (2002-10-01), pages 92 - 97, XP002505898, ISSN: 0008-8749 *

Also Published As

Publication number Publication date
JP2007116947A (en) 2007-05-17
US20080317757A1 (en) 2008-12-25
EP1947178A1 (en) 2008-07-23
US7935795B2 (en) 2011-05-03
JP4736037B2 (en) 2011-07-27
WO2007049472A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
EP1947178A4 (en) Human monoclonal antibody binding to human gm-csf and antigen-binding site thereof
IL231169A0 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
HK1232230A1 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same cd134(ox40)
IL179672A (en) Human monoclonal anti-cd3 antibodies
IL191340A (en) Human monoclonal antibodies to o8e
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
HK1098825A1 (en) Human monoclonal antibodies against cd20
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1940466A4 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (en) Monoclonal antibody and use thereof
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
ZA200905874B (en) Monoclonal human tumor-specific antibody
EP2077325A4 (en) Monoclonal antibody and use thereof
EP1819733A4 (en) Monoclonal antibody to human tgf-beta induced gene-h3 and use thereof
ZA200804254B (en) Human monoclonal antibodies to O8E
EP1712564A4 (en) Anti-nc1 monoclonal antibody
GB0415644D0 (en) Monoclonal antibody
EP1944323A4 (en) Novel monoclonal antibody and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090210

17Q First examination report despatched

Effective date: 20090422

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20131010